Combination valsartan and dapagliflozin improves blood pressure and glucose in Type 2 Diabetes and hypertension.
Photo by Navy Medicine / Unsplash
Key Takeaway
Consider that combination valsartan and dapagliflozin may improve cardiometabolic parameters in patients with Type 2 Diabetes and hypertension, based on observational data.
This was a retrospective cohort study of 245 patients with coexisting Type 2 Diabetes Mellitus and hypertension. Patients were assigned to either combination therapy (valsartan 80 mg/day + dapagliflozin 10 mg/day; n=102) or monotherapy (valsartan 80 mg/day; n=102) with a 24-week follow-up.
The combination group showed a greater reduction in systolic blood pressure (134.86 ± 6.37 mmHg vs. 139.68 ± 6.82 mmHg; P < 0.001) and diastolic blood pressure (83.12 ± 4.58 mmHg vs. 86.29 ± 4.79 mmHg; P < 0.001). Fasting plasma glucose was lower in the combination group (6.79 ± 1.02 mmol/L vs. 7.58 ± 1.10 mmol/L; P < 0.001), as was the 2-hour postprandial glucose (9.71 ± 1.68 mmol/L vs. 11.24 ± 1.84 mmol/L; P < 0.001). Glycemic variability indices also improved more with combination therapy (P < 0.001).
Inflammatory and cardiac biomarkers showed a more marked decline in the combination group (P < 0.05). Left ventricular ejection fraction improved significantly (60.12 ± 4.68% vs. 56.75 ± 4.96%; P < 0.05), and NT-proBNP, renal function, and fibrosis markers also improved more in the combination group (all P < 0.05). Multivariate analysis indicated combination therapy independently predicted better outcomes (OR = 2.417, 95% CI: 1.315–4.443, P = 0.004).
Safety and tolerability were not reported. The study was observational, limiting causal inference, and key details like primary outcome and practice relevance were not reported. These findings suggest potential benefits of combination therapy but require confirmation in randomized trials.
More on Hypertension
Sacubitril/valsartan shows greater LVMI regression than some antihypertensives in hypertension with remodeling
New Drug Shrinks Heart Muscle Better Than Old Options
A network meta-analysis of 851 patients with essential hypertension and cardiovascular remodeling found sacubitril/valsartan achieved greate…
A new analysis shows one specific medicine shrinks thickened heart muscle better than older blood pressure treatments, offering hope for rev…
Phase 4 trial compares pioglitazone versus dapagliflozin add-on in type 2 diabetes
Trial compares two diabetes drug combinations but results are not yet available
A phase 4 randomized controlled trial in South Korea enrolled 133 participants with type 2 diabetes inadequately controlled by DPP-4 inhibit…
A completed trial in South Korea compared two three-drug combinations for type 2 diabetes, but results on blood sugar control are not yet av…
Systematic review shows regional differences in HS comorbidity prevalence across North America, Europe, and Asia.
Regional differences in health risks for hidradenitis suppurativa patients
This systematic review and meta-analysis examines the prevalence of hidradenitis suppurativa-associated comorbidities across North America, …
A meta-analysis reveals how hidradenitis suppurativa patients in North America, Europe, and the Middle East/Asia face different odds for dia…
Zibotentan plus dapagliflozin shows no HVPG reduction in compensated cirrhosis
Early trial shows zibotentan plus dapagliflozin trended toward lowering blood pressure in cirrhosis patients
This Phase II randomized placebo-controlled exploratory study in 28 patients with compensated cirrhosis found that zibotentan 2.5 mg plus da…
An early study found that a combination drug lowered blood pressure in patients with compensated cirrhosis, though it did not conclusively i…
View Original Abstract ↓
BackgroundHypertension and Type 2 Diabetes Mellitus (T2DM) interact to increase cardiorenal risk. This study evaluated the cardiorenal efficacy of dapagliflozin combined with valsartan in patients with coexisting T2DM and hypertension.MethodsThis retrospective cohort study included 245 patients admitted between January 2023 and December 2024. Propensity score matching yielded 102 patients in the Monotherapy Group (valsartan 80 mg/day) and 102 in the Combination Group (valsartan 80 mg/day + dapagliflozin 10 mg/day). Outcomes assessed at baseline and 24 weeks included blood pressure, glycemic parameters (FPG, 2hPG, GluCV, PGE, LAGE, MAGE), inflammatory and cardiac biomarkers (hs-CRP, TNF-α, IL-6, IL-33, sST2, sICAM-1), echocardiographic measures (LVEF, LVEDD, LVESD, LAD, IVSd), NT-proBNP, renal function (eGFR, UACR, SCr, BUN), and fibrosis markers (PIIINP, C-IV, LN, TGF-β1).ResultsAt 24 weeks, the Combination Group showed greater reductions in systolic (134.86 ± 6.37 vs. 139.68 ± 6.82 mmHg) and diastolic blood pressure (83.12 ± 4.58 vs. 86.29 ± 4.79 mmHg), FPG (6.79 ± 1.02 vs. 7.58 ± 1.10 mmol/L), 2hPG (9.71 ± 1.68 vs. 11.24 ± 1.84 mmol/L), and glycemic variability indices (all P < 0.001). Inflammatory and cardiac biomarkers declined more markedly (P < 0.05). Significant improvements were also observed in LVEF (60.12 ± 4.68% vs. 56.75 ± 4.96%), NT-proBNP, eGFR, UACR, and fibrosis markers (all P < 0.05). Multivariate analysis showed combination therapy independently predicted better outcomes (OR = 2.417, 95% CI: 1.315–4.443, P = 0.004).ConclusionThe addition of dapagliflozin to valsartan was associated with superior cardiorenal outcomes compared to valsartan monotherapy in patients with T2DM and hypertension, as evidenced by enhanced improvements in blood pressure, glycemic control, inflammation, cardiac function, and renal parameters.
Tirzepatide MTD Demonstrates Cost-Effectiveness Versus Semaglutide MTD in Obesity Simulation Modeling Study
Tirzepatide Saves Money and Health Over Semaglutide
Related in Diabetes & Endocrinology
Review of NHANES data links metformin use to lower mortality and inflammatory markers in type 2 diabetes
Metformin use linked to lower death risk and better inflammation markers in U.S. adults with diabetes
This review of NHANES 2013-2018 data (2,116 adults) found that metformin use was associated with lower all-cause and cardiovascular mortalit…
New analysis of U.S. adults with diabetes suggests metformin use connects to lower death risk and improved inflammation markers, though more…
A 1-month nudge-based dietary intervention increased daily step counts by 1105 steps at 3 months in adults with type 2 diabetes.
Small diet changes might boost steps for a short time in diabetes care
This cluster-randomised controlled trial enrolled 204 adults aged 18-59 years with type 2 diabetes across 12 primary healthcare centres in B…
A simple diet plan helped people with diabetes walk more for three months but the extra steps did not stick in the long run
Mobile app plus group sessions showed feasibility in Malaysian women with gestational diabetes
A new app plus support for diabetes care in Malaysia showed no benefit yet.
This feasibility randomized controlled trial enrolled 60 women with gestational diabetes mellitus in Malaysia. The intervention included mob…
A trial in Malaysia found that a mobile app and group sessions did not improve health outcomes for women with gestational diabetes compared …
Oral Sodium Butyrate Reduces Weight in Overweight Adults Without Diabetes
Oral sodium butyrate helps overweight adults without diabetes lose weight
This 12-week proof-of-concept RCT in 46 overweight adults (23 with type 2 diabetes) found that oral sodium butyrate 1875 mg/day led to great…
A new trial shows oral sodium butyrate helps adults without diabetes lose more weight than a placebo over three months.
From Other Specialties
Systematic review and meta-analysis shows cefotiam reduces postoperative infection in clean surgery
Cefotiam cuts post-surgery infection risk by half compared to no antibiotics
This systematic review and meta-analysis evaluated cefotiam prophylaxis versus no antibiotic prophylaxis or other beta-lactam agents in adul…
A large review found cefotiam lowers infection risk after clean surgery. It works as well as other common antibiotics without causing more s…
Therapeutic Touch Reduces Crying and Improves Sleep in Infants With Colic
Therapeutic touch reduces crying in babies with colic
This randomized controlled trial in 96 infants with colic found that therapeutic touch based on Watson's Human Care Theory significantly red…
A new trial shows gentle therapeutic touch helps babies cry less and sleep better when they have infantile colic.
Mycophenolate mofetil non-inferior to prednisone for first-episode nephrotic syndrome in children
Mycophenolate Mofetil Offers Alternative to Steroids for Nephrotic Syndrome
This phase 3 non-inferiority trial randomized 272 children aged 1-10 years with first-episode steroid-sensitive nephrotic syndrome to mycoph…
A new trial shows mycophenolate mofetil works as well as prednisone for children with nephrotic syndrome, with fewer steroid side effects.
AquOTic water competency intervention improves outcomes in children with autism
Water therapy improves skills for children with autism spectrum disorder
This pre-post cohort study of 37 children with autism ages 5 to 9 found that a 10-week occupational therapy-based water competency intervent…
A water-based occupational therapy program significantly improved performance and satisfaction scores in children with autism spectrum disor…